Meda: FDA Requests More Information on New Azelastine Formulation
STOCKHOLM, Sweden--(BUSINESS WIRE)--Jun 3, 2008 - The U.S. Food and Drug Administration (FDA) has requested more information on Meda's new drug application concerning azelastine hydrochloride nasal spray in a new formulation. Meda will initiate a discussion with the FDA to understand and clarify the needs of FDA and what steps need to be taken before the application may be approved. This process is anticipated to take several months before conclusion.
MEDA AB (publ) is an international specialty pharma company that concentrates on marketing and market-adapted product development. Acquisitions and long-term partnerships are fundamental factors that drive the company's strategy. Meda is represented with own organisations in 26 countries and with more than 1 500 employees within marketing and sales. Meda's products are sold in approximately 120 countries world-wide. The Meda share is listed under Large Cap on the OMX Nordic Stock Exchange. Find out more, visit www.meda.se.
This information was brought to you by Cision http://newsroom.cision.com.
Contact
MEDA AB
Investor Relations:
Anders Larnholt, +46 8 630 19 62 / +46 709 458 878
anders.larnholt@meda.se
Posted: June 2008
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
